RetinalGenix Technologies (RTGN) Cash from Financing Activities (2020 - 2026)
RetinalGenix Technologies (RTGN) reported Cash from Financing Activities of $94619.0 for Q1 2026, down 48.82% on a YoY basis from $184873.0 in Q1 2025, and down 33.79% sequentially from $142901.0 in Q4 2025.
RetinalGenix Technologies (RTGN) Cash from Financing Activities (2020 - 2026) Analysis & Trends
RetinalGenix Technologies (RTGN) has 7 years of Cash from Financing Activities data on file, last reported at $94619.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities fell 48.82% year-over-year to $94619.0; the trailing twelve-month figure through Mar 2026 stood at $476810.0 (down 33.65% YoY), and the FY2025 full-year result was $567064.0, down 24.19% from the prior year.
- Cash from Financing Activities retreated to $94619.0 in Q1 2026, from $142901.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $289981.0 in Q4 2023 to a low of -$41618.0 in Q3 2023.
- A 5-year average of $120940.4 and a median of $113361.0 in 2024 frame the typical range for Cash from Financing Activities.
- Peak annual rise in Cash from Financing Activities reached 1418.79% in 2023, while the deepest fall reached 166.22% in 2023.
- Tracing RTGN's Cash from Financing Activities over 5 years: stood at $29651.0 in 2022, then soared by 877.98% to $289981.0 in 2023, then sank by 60.91% to $113361.0 in 2024, then increased by 26.06% to $142901.0 in 2025, then sank by 33.79% to $94619.0 in 2026.
- Business Quant data shows RTGN's Cash from Financing Activities at $94619.0 in Q1 2026, $142901.0 in Q4 2025, and $103090.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | RetinalGenix Technologies | 75.02 Mn | 75.02 Mn | - | 94,619.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 94,619.00 |
| Mar 31, 2026 | 94,619.00 |
| Dec 31, 2025 | 142,901.00 |
| Dec 31, 2025 | 142,901.00 |
| Sep 30, 2025 | 103,090.00 |
| Sep 30, 2025 | 103,090.00 |
| Jun 30, 2025 | 136,200.00 |
| Jun 30, 2025 | 136,200.00 |
| Mar 31, 2025 | 184,873.00 |
| Mar 31, 2025 | 184,873.00 |
| Dec 31, 2024 | 113,361.00 |
| Dec 31, 2024 | 113,361.00 |
| Sep 30, 2024 | 239,108.00 |
| Sep 30, 2024 | 239,108.00 |
| Jun 30, 2024 | 181,322.00 |
| Jun 30, 2024 | 181,322.00 |
| Mar 31, 2024 | 214,205.00 |
| Mar 31, 2024 | 214,205.00 |
| Dec 31, 2023 | 289,981.00 |
| Dec 31, 2023 | 289,981.00 |